Project Grant P01AI202868
Award Date 9/1/26
Completion Date 7/31/31
Dollars Obligated $2.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $211,875 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test conditional knockdown mutants of Mycobacterium tuberculosis in C3HEB/FEJ mice with human-like tuberculosis pathology. The research analyzes conditional mutants deficient in thioredoxin reductase (TRXB2) and biotin protein ligase (BPL) to determine their ability to...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $3.589 million on May 26, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a basic-science foundation for developing tuberculosis treatment-shortening drugs and regimens. The award funds four integrated research projects addressing the biological determinants of treatment duration in Mycobacterium tuberculosis infections. Project 1 examines...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $861,485 in Project Grant R01AI187561 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds investigation of regulatory T cell (Treg)-inducing peptides as an immune-evasion mechanism in pathogen molecular mimicry. The research examines how pathogen-derived peptides, particularly the TB9 peptide from Mycobacterium tuberculosis, can...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Weill Medical College of Cornell University a $2.94 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 23, 2025, with a completion date of June 30, 2029. This research initiative aims to advance understanding of resistance and tolerance mechanisms to nitroimidazole antibiotics (pretomanid and delamanid) in Mycobacterium tuberculosis, the...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $254,249 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to combine host-directed and pathogen-directed therapeutic approaches against Mycobacterium tuberculosis by exploiting the organism's dependence on cholesterol metabolism. The research will investigate inhibition of two enzymatic targets: MTB's phosphopantetheinyl transferase (PPTT), which...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $110,228 on February 14, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map genetic interactions in mycobacteria and apply those maps to tuberculosis drug discovery and regimen design. The award funds large-scale genetic interaction mapping in Mycobacterium tuberculosis and the model organism M. smegmatis using a CRISPR interference platform for...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $442,146 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate salicylate-based drugs as adjuvants to potentiate bedaquiline's anti-tuberculosis activity. The project addresses rising rates of low-level resistance to bedaquiline, the current backbone of second-line regimens for drug-resistant tuberculosis. Preliminary data show...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $419,082 on September 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to mentor multidisciplinary research on multidrug-resistant tuberculosis adherence and emergent drug resistance. The award funds mentorship-driven research to train a new cadre of clinical investigators in patient-oriented research addressing multidrug-resistant TB...
- The National Institute of Allergy and Infectious Diseases awarded Albany Medical College $451,000 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of Wnt/β-catenin signaling in alveolar epithelial repair during tuberculosis infection. The research addresses how chronic type I interferon signaling suppresses Wnt/β-catenin activity and impairs lung regeneration in tuberculosis-susceptible mice. The project encompasses three aims:...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $315,700 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research elucidating spatio-temporal innate immune cell modulation of Mycobacterium tuberculosis stress response and replication heterogeneity. The project investigates how spatial organization of tuberculosis lesions in the lung...